株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

冠動脈疾患 (CAD):世界の治験レビュー

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 240579
出版日 ページ情報 英文 1479 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.37円で換算しております。
Back to Top
冠動脈疾患 (CAD):世界の治験レビュー Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017
出版日: 2017年07月19日 ページ情報: 英文 1479 Pages
概要

当レポートでは、世界の冠動脈疾患 (CAD)治療薬の臨床試験について調査し、 地域別の臨床試験数データ、試験段階、試験状況、採用テーマおよびスポンサー企業タイプ別の臨床試験データ、 中断(一時中止、廃止、打ち切り)された試験のリストなどを提供しており、概略以下の構成でお届けします。

目次

  • イントロダクション
    • 冠動脈疾患 (CAD)
    • レポートガイダンス
  • 臨床試験: 地域別
  • 臨床試験: 国別
    • 臨床試験に寄与している主要5ヵ国 − アジア太平洋地域
    • 臨床試験に寄与している主要5ヵ国 − 欧州
    • 臨床試験に寄与している主要国 − 北米
    • 臨床試験に寄与している主要5ヵ国 − 中東およびアフリカ
    • 臨床試験に寄与している主要5ヵ国 − 中南米
  • 臨床試験 BRIC 諸国
  • 臨床試験 G7 諸国
  • 臨床試験 G7 諸国 , 治験ステータス別
  • 臨床試験 E7 諸国
  • 臨床試験 E7 諸国 , 治験ステータス別
  • 相別臨床試験
    • 進行中の治験:相別
  • 臨床試験: 治験ステータス別
  • 未完了の治験
  • 期間ごとの被験者数
  • 有力なスポンサー
    • 主な治験参加企業
  • 有望な治療薬比較
  • 臨床試験プロファイル
    • 臨床試験概要: 主要企業
      • Abbott Laboratories
      • Boston Scientific Corporation
      • Cordis Corporation
      • Medtronic, Inc.
      • Johnson & Johnson
      • AstraZeneca PLC
      • GE Healthcare
      • Pfizer Inc.
      • Gilead Sciences, Inc.
      • Eli Lilly and Company
      • POINT Biomedical Corporation
      • Sahajanand Medical Technologies Pvt. Ltd.
      • Lantheus Medical Imaging, Inc.
      • アステラス製薬
      • Cook
      • Bracco Diagnostics, Inc.
      • Sanofi
      • Intermountain Healthcare, Inc.
      • Forest Laboratories, Inc.
      • 小野薬品工業
    • 臨床試験概要: トップレベルの大学 / 研究機関 / 病院
      • Seoul National University Hospital
      • Sapienza University of Rome
      • University of Ottawa Heart Institute
      • Yonsei University
      • 熊本大学
      • Emory University
      • University Hospital Inselspital, Berne
      • Norwegian University of Science and Technology
      • National Taiwan University Hospital
      • MedStar Health Research Institute
      • 京都大学
      • Samsung Medical Center
      • University of Sao Paulo
      • Deutsches Herzzentrum Munchen
      • Mayo Clinic
      • Oslo University Hospital
      • University of Leipzig
      • Massachusetts General Hospital
      • Skejby Hospital
      • Montreal Heart Institute Research Centre
  • 5つの主要な臨床プロファイル

付録

図表一覧


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4339CTIDB

GlobalData's clinical trial report, "Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 27
  • In Progress Trials by Phase 28
  • Clinical Trials by Trial Status 29
  • Clinical Trials by End Point Status 31
  • Subjects Recruited Over a Period of Time 32
  • Clinical Trials by Sponsor Type 33
  • Prominent Sponsors 34
  • Top Companies Participating in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials 36
  • Prominent Drugs 38
  • Latest Clinical Trials News on Coronary Artery Disease (CAD) (Ischemic Heart Disease) 40
  • Jun 28, 2017: Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone 40
  • Jun 27, 2017: Merck Provides Update on REVEAL Outcomes Study of Anacetrapib 40
  • Clinical Trial Profile Snapshots 41

Appendix 1477

  • Abbreviations 1477
  • Definitions 1477
  • Research Methodology 1478
  • Secondary Research 1478
  • About GlobalData 1479
  • Contact Us 1479
  • Source 1479

List of Tables

List of Tables

  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 18
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 23
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase, 2017* 27
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39

List of Figures

List of Figures

  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 17
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 22
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
  • GlobalData Methodology 1478
Back to Top